Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. NDAQ
9. TSCO
10. BE

Go back to Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs

Incyte (INCY) PT Raised to $146 at BMO Capital

May 5, 2017 9:13 AM EDT

BMO Capital raised its price target on Incyte (NASDAQ: INCY) to $146.00 (from $144.00) while maintaining a Outperform rating following strong Jakafi results in Q1.

Analyst M. Ian Somaiya commented, "While polycythemia vera (PV) continues to be a growth driver, graft vs host... More

Incyte (INCY) Tops Q1 EPS by 4c

May 4, 2017 7:15 AM EDT

Incyte (NASDAQ: INCY) reported Q1 EPS of ($0.96), $0.04 better than the analyst estimate of ($1.00). Revenue for the quarter came in at $384.08 million versus the consensus estimate of $358.27 million.

Cash, cash equivalents and marketable securities position As of March 31, 2017, cash, cash equivalents and marketable securities... More